AFFILIATIONS
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
9 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
10 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
11 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
12 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
13 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
14 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
15 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
ABSTRACT
Background: Bispecific antibodies (BsAbs) and chimeric antigen receptor T-cell (CAR-T) therapy have reshaped treatment paradigms for relapsed/refractory (R/R) aggressive B-cell lymphoma. Bridging therapy during CAR-T manufacturing is crucial to prevent disease progression and preserve patient fitness. Glofitamab, a CD20×CD3 bispecific antibody with rapid onset and chemotherapy-independent efficacy, is a promising bridging candidate. However, clinical evidence for BsAb bridging prior to CAR-T therapy, with or without autologous stem cell transplantation (CAR-T±ASCT), remains limited. Here, we prospectively evaluated the efficacy, safety, and clinical synergy of sequential glofitamab bridging and cellular therapy.
Methods: In this prospective trial (NCT06996132), patients with R/R aggressive B-cell lymphoma received glofitamab-containing bridging regimens—as monotherapy, or combined with immunochemotherapy or targeted agents—followed by CAR-T±ASCT. The choice between CAR-T alone and CAR-T+ASCT was individualized according to stem cell mobilization/collection status, age and performance status, and prior transplant history. The primary endpoint was complete response rate (CRR) post-CAR-T±ASCT. Response was evaluated using Lugano criteria, and cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were graded via ASTCT consensus criteria across both treatment phases. Progression-free survival (PFS) and overall survival (OS) were calculated from bridging initiation using the Kaplan–Meier method.
Results: Between April 2024 and May 2026, 36 patients were enrolled. Median age was 54 years (range 21–75), with a male-to-female ratio of 5:4. High disease burden or high-risk features were prevalent: 88.9% Ann Arbor stage III–IV, 77.8% elevated lactate dehydrogenase, and TP53 mutation/deletion in 54.8% of evaluable patients (17/31). Patients had received a median of 2 prior lines (range 1–5). Bridging therapy consisted of glofitamab monotherapy in 9 patients (25.0%), glofitamab plus immunochemotherapy in 22 (61.1%), and glofitamab plus small-molecule/targeted agents in 5 (13.9%). Subsequently, 21 patients (58.3%) received CAR-T+ASCT and 15 (41.7%) received CAR-T alone. The objective response rate (ORR) after bridging was 94.4% (CRR 38.9%, partial response 55.6%). Following CAR-T±ASCT, the best ORR reached 100% with a best CRR of 86.1%. At a median follow-up of 10 months (range 2–29), 5 patients had disease progression and 2 died (1 from progression, 1 from a treatment-unrelated complication). Estimated 1-year PFS and OS were 72.6% and 90.4%, respectively. No grade ≥3 CRS occurred. During bridging, CRS was observed in 50.0% (18/36), with grade 2 in 5.6% (2/36). During CAR-T±ASCT, CRS occurred in 91.7% (33/36), with grade 2 in 2.8% (1/36). No ICANS developed during bridging; 1 patient (2.8%) had grade 3 ICANS following CAR-T±ASCT.
Conclusions: Glofitamab-based bridging before CAR-T±ASCT achieves deep, durable responses with favorable safety in R/R aggressive B-cell lymphoma. Sequential BsAb bridging and CAR-T+ASCT demonstrate strong clinical synergy without compounding severe immune toxicities, offering a viable strategy to optimize long-term outcomes.